001     179901
005     20241219120840.0
024 7 _ |a 10.1002/ijc.34027
|2 doi
024 7 _ |a pmid:35411591
|2 pmid
024 7 _ |a 0020-7136
|2 ISSN
024 7 _ |a 1097-0215
|2 ISSN
024 7 _ |a altmetric:126482420
|2 altmetric
037 _ _ |a DKFZ-2022-00958
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Khalid, Umar
|0 P:(DE-He78)794761a765ceca759536a1bf39100142
|b 0
|e First author
|u dkfz
245 _ _ |a A synergistic interaction between HDAC- and PARP inhibitors in childhood tumors with chromothripsis.
260 _ _ |a Bognor Regis
|c 2022
|b Wiley-Liss
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1656680403_3318
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:B420#LA:B420# / 2022 Aug 15;151(4):590-606
520 _ _ |a Chromothripsis is a form of genomic instability characterized by the occurrence of tens to hundreds of clustered DNA double-strand breaks in a one-off catastrophic event. Rearrangements associated with chromothripsis are detectable in numerous tumor entities and linked with poor prognosis in some of these, such as Sonic Hedgehog medulloblastoma, neuroblastoma and osteosarcoma. Hence, there is a need for therapeutic strategies eliminating tumor cells with chromothripsis. Defects in DNA double-strand break repair, and in particular homologous recombination repair, have been linked with chromothripsis. Targeting DNA repair deficiencies by synthetic lethality approaches, we performed a synergy screen using drug libraries (n = 375 compounds, 15 models) combined with either a PARP inhibitor or cisplatin. This revealed a synergistic interaction between the HDAC inhibitor romidepsin and PARP inhibition. Functional assays, transcriptome analyses and in vivo validation in patient-derived xenograft mouse models confirmed the efficacy of the combinatorial treatment.
536 _ _ |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312)
|0 G:(DE-HGF)POF4-312
|c POF4-312
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a HDAC inhibitor
|2 Other
650 _ 7 |a PARP inhibitor
|2 Other
650 _ 7 |a chromothripsis
|2 Other
650 _ 7 |a synergy
|2 Other
650 _ 7 |a synthetic lethality
|2 Other
700 1 _ |a Simovic, Milena
|0 P:(DE-He78)1fdaffee272e57a73f861a0ea36c4079
|b 1
|u dkfz
700 1 _ |a Hammann, Linda A
|0 P:(DE-He78)6268906e54e5ca1f69e966a42d92bff7
|b 2
|u dkfz
700 1 _ |a Iskar, Murat
|0 P:(DE-He78)f28fcc92d5c00f3ee511e3319c699b38
|b 3
|u dkfz
700 1 _ |a Wong, John K L
|0 P:(DE-HGF)0
|b 4
700 1 _ |a Kumar, Rithu
|0 P:(DE-He78)c5cc0ee57f0d49302de5365f8cb9206e
|b 5
|u dkfz
700 1 _ |a Jugold, Manfred
|0 P:(DE-He78)f12dec7b80065347181cf69f8233b40d
|b 6
|u dkfz
700 1 _ |a Sill, Martin
|0 P:(DE-He78)45440b44791309bd4b7dbb4f73333f9b
|b 7
|u dkfz
700 1 _ |a Bolkestein, Michiel
|0 P:(DE-He78)2f672b5ff4fc0d5ba62362e2be763b33
|b 8
700 1 _ |a Kolb, Thorsten
|0 P:(DE-He78)ff4b82323a90d759d3c7eef0fd8ddfe3
|b 9
|u dkfz
700 1 _ |a Hergt, Michaela
|0 P:(DE-He78)0a9866797138423749f3c3b00d53e1cc
|b 10
|u dkfz
700 1 _ |a Devens, Frauke
|0 P:(DE-He78)83cd6bd6ea17b47e625c371d6415bdea
|b 11
|u dkfz
700 1 _ |a Ecker, Jonas
|0 P:(DE-He78)3de637452ba900e2bdd359b8f41953bf
|b 12
|u dkfz
700 1 _ |a Kool, Marcel
|0 P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8
|b 13
|u dkfz
700 1 _ |a Milde, Till
|0 P:(DE-He78)0be2f86573954f87e97f8a4dbb05cb0f
|b 14
|u dkfz
700 1 _ |a Westermann, Frank
|0 P:(DE-He78)91f32735ee876c579d63c05a7f4778dd
|b 15
|u dkfz
700 1 _ |a Benner, Axel
|0 P:(DE-He78)e15dfa1260625c69d6690a197392a994
|b 16
|u dkfz
700 1 _ |a Lewis, Joe
|b 17
700 1 _ |a Dietrich, Sascha
|b 18
700 1 _ |a Pfister, Stefan M
|0 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
|b 19
|u dkfz
700 1 _ |a Lichter, Peter
|0 P:(DE-He78)e13b4363c5fe858044ef8a39c02c870c
|b 20
|u dkfz
700 1 _ |a Zapatka, Marc
|0 P:(DE-He78)1beba8f953e7ae7e96e8d3e9a48f10f7
|b 21
|u dkfz
700 1 _ |a Ernst, Aurélie
|0 P:(DE-He78)509fb81813c1911954da583129e8ea57
|b 22
|e Last author
|u dkfz
773 _ _ |a 10.1002/ijc.34027
|g p. ijc.34027
|0 PERI:(DE-600)1474822-8
|n 4
|p 590-606
|t International journal of cancer
|v 151
|y 2022
|x 0020-7136
909 C O |o oai:inrepo02.dkfz.de:179901
|p VDB
|p OpenAPC
|p openCost
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)794761a765ceca759536a1bf39100142
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)1fdaffee272e57a73f861a0ea36c4079
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)6268906e54e5ca1f69e966a42d92bff7
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)f28fcc92d5c00f3ee511e3319c699b38
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)c5cc0ee57f0d49302de5365f8cb9206e
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)f12dec7b80065347181cf69f8233b40d
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-He78)45440b44791309bd4b7dbb4f73333f9b
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 8
|6 P:(DE-He78)2f672b5ff4fc0d5ba62362e2be763b33
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 9
|6 P:(DE-He78)ff4b82323a90d759d3c7eef0fd8ddfe3
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-He78)0a9866797138423749f3c3b00d53e1cc
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 11
|6 P:(DE-He78)83cd6bd6ea17b47e625c371d6415bdea
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 12
|6 P:(DE-He78)3de637452ba900e2bdd359b8f41953bf
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 13
|6 P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 14
|6 P:(DE-He78)0be2f86573954f87e97f8a4dbb05cb0f
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 15
|6 P:(DE-He78)91f32735ee876c579d63c05a7f4778dd
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 16
|6 P:(DE-He78)e15dfa1260625c69d6690a197392a994
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 19
|6 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 20
|6 P:(DE-He78)e13b4363c5fe858044ef8a39c02c870c
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 21
|6 P:(DE-He78)1beba8f953e7ae7e96e8d3e9a48f10f7
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 22
|6 P:(DE-He78)509fb81813c1911954da583129e8ea57
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-312
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Funktionelle und strukturelle Genomforschung
|x 0
914 1 _ |y 2022
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2021-02-04
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-02-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-02-04
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-02-04
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2022-11-25
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2022-11-25
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b INT J CANCER : 2021
|d 2022-11-25
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b INT J CANCER : 2021
|d 2022-11-25
915 p c |a APC keys set
|2 APC
|0 PC:(DE-HGF)0000
915 p c |a Local Funding
|2 APC
|0 PC:(DE-HGF)0001
920 2 _ |0 I:(DE-He78)B420-20160331
|k B420
|l Genominstabilität in Tumoren
|x 0
920 1 _ |0 I:(DE-He78)B420-20160331
|k B420
|l Genominstabilität in Tumoren
|x 0
920 1 _ |0 I:(DE-He78)B060-20160331
|k B060
|l B060 Molekulare Genetik
|x 1
920 1 _ |0 I:(DE-He78)W240-20160331
|k W240
|l Core Facility Kleinbildgebung
|x 2
920 1 _ |0 I:(DE-He78)B062-20160331
|k B062
|l B062 Pädiatrische Neuroonkologie
|x 3
920 1 _ |0 I:(DE-He78)HD01-20160331
|k HD01
|l DKTK HD zentral
|x 4
920 1 _ |0 I:(DE-He78)B310-20160331
|k B310
|l KKE Pädiatrische Onkologie
|x 5
920 1 _ |0 I:(DE-He78)B087-20160331
|k B087
|l B087 Neuroblastom Genomik
|x 6
920 1 _ |0 I:(DE-He78)C060-20160331
|k C060
|l C060 Biostatistik
|x 7
920 0 _ |0 I:(DE-He78)B420-20160331
|k B420
|l Genominstabilität in Tumoren
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B420-20160331
980 _ _ |a I:(DE-He78)B060-20160331
980 _ _ |a I:(DE-He78)W240-20160331
980 _ _ |a I:(DE-He78)B062-20160331
980 _ _ |a I:(DE-He78)HD01-20160331
980 _ _ |a I:(DE-He78)B310-20160331
980 _ _ |a I:(DE-He78)B087-20160331
980 _ _ |a I:(DE-He78)C060-20160331
980 _ _ |a UNRESTRICTED
980 _ _ |a APC


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21